T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 7.305 USD -2.6% Market Closed
Market Cap: 365m USD

TriSalus Life Sciences Inc
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

TriSalus Life Sciences Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
T
TriSalus Life Sciences Inc
NASDAQ:TLSI
Change in Working Capital
-$9.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Flame Acquisition Corp
NYSE:SOC
Change in Working Capital
$38.9m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Solid Power Inc
NASDAQ:SLDP
Change in Working Capital
$3.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Core Scientific Inc
NASDAQ:CORZ
Change in Working Capital
-$27.6m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Symbotic Inc
NASDAQ:SYM
Change in Working Capital
$714m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Rumble Inc
NASDAQ:RUM
Change in Working Capital
-$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
364.5m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
4.113 USD
Overvaluation 44%
Intrinsic Value
Price
T

See Also

What is TriSalus Life Sciences Inc's Change in Working Capital?
Change in Working Capital
-9.5m USD

Based on the financial report for Dec 31, 2024, TriSalus Life Sciences Inc's Change in Working Capital amounts to -9.5m USD.

Back to Top